Reversion of patients with chronic migraine to an episodic migraine classification with fremanezumab treatment (vol 19, P7, 2018)

被引：0
|
作者：
Cohen, Joshua M. [1 ]
Bibeau, Kristen [1 ]
Galic, Maja [2 ]
Seminerio, Michael J. [1 ]
Ramirez Campos, Verena [3 ]
Singh, Rashmi B. Halker [4 ]
Ailani, Jessica [5 ]
机构：
[1] Teva Pharmaceut, Frazer, PA 19355 USA
[2] Teva Pharmaceut, Amsterdam, Netherlands
[3] Teva Pharmaceut, Buenos Aires, DF, Argentina
[4] Mayo Clin, Phoenix, AZ USA
[5] Medstar Georgetown Univ Hosp, Washington, DC USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective
    Takeshima, Takao
    Sakai, Fumihiko
    Wang, Xinyu
    Yamato, Kentaro
    Kojima, Yoshitsugu
    Zhang, Yilong
    Bennison, Craig
    Simons, Martijn J. H. G.
    PHARMACOECONOMICS, 2024, 42 (07) : 811 - 822
  • [42] Efficacy of Long-Term Fremanezumab Treatment in Patients with Chronic or Episodic Migraine and Prior Inadequate Response to Multiple Migraine Preventive Medication Classes
    Naegel, Steffen
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Barash, Steve
    Ning, Xiaoping
    Carr, Karen
    Kudrow, David
    ANNALS OF NEUROLOGY, 2021, 90 : S132 - S133
  • [43] Reversion of chronic to episodic migraine in working age and botulinum toxin-resistant patients treated with fremanezumab: A real-life study
    Tudela-Tomas, Juan
    Ramos-Guerrero, Rosa-Maria
    Rodriguez-Mateos, Maria-Eugenia
    BRAIN AND BEHAVIOR, 2024, 14 (07):
  • [44] Impact of fremanezumab on response rates, acute medication use, and disability in patients with episodic migraine who have failed at least one prior migraine preventive medication (vol 19, 119, 2018)
    Winner, Paul K.
    Singh, Rashmi B. Halker
    Cohen, Joshua M.
    Yang, Ronghua
    Yeung, Paul P.
    Ramirez Campos, Verena
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [45] Clinically meaningful responses to fremanezumab treatment in episodic and chronic migraine over up to 15 months
    Nahas, S. J.
    Cohen, J. M.
    Campos, Ramirez, V
    Ning, X.
    Janka, L.
    Dodick, D. W.
    HEADACHE, 2021, 61 : 114 - 115
  • [46] MEDICATION OVERUSE REVERSION FOLLOWING FREMANEZUMAB TREATMENT IN MIGRAINE PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVES
    Ashina, Sait
    Campos, Verena Ramirez
    Cohen, Joshua
    Janka, Lindsay
    Krasenbaum, Lynda
    Blume, Lydia
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09)
  • [47] Safety and Tolerability of Fremanezumab in Patients with Episodic and Chronic Migraine: A Pooled Analysis of Phase 3 Studies
    McAllister, Peter
    Ning, Xiaoping
    Kessler, Yoel
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Yang, Ronghua
    ANNALS OF NEUROLOGY, 2020, 88 : S158 - S159
  • [48] Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
    Diener, Hans Christoph
    McAllister, Peter
    Jurgens, Tim P.
    Kessler, Yoel
    Ning, Xiaoping
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Barash, Steve
    Silberstein, Stephen D.
    CEPHALALGIA, 2022, 42 (08) : 769 - 780
  • [49] Cardiovascular Safety of Fremanezumab in Patients with Episodic and Chronic Migraine: A Pooled Analysis of Phase 3 Studies
    Nahas, Stephanie J.
    Kessler, Yoel
    Ning, Xiaoping
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Yang, Ronghua
    Silberstein, Stephen D.
    NEUROLOGY, 2020, 94 (15)
  • [50] Safety and Tolerability of Fremanezumab in Patients With Episodic and Chronic Migraine: a Pooled Analysis of Phase 3 Studies
    Vargas, Bert B.
    Ning, Xiaoping
    Kessler, Yoel
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Yang, Ronghua
    McAllister, Peter
    NEUROLOGY, 2020, 94 (15)
12345